9:30 AM
Jan 11, 2019
 |  BC Week In Review  |  Company News  |  Deals

Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002)...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >